New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab

References

• American Cancer SocietyCancer Facts and Figures 2015Atlanta, GAAmerican Cancer Society2015
   Google Scholar
• DesaiAEl-BakkarHAbdul-HayMNovel agents in the treatment of chronic lymphocytic leukemia: a review about the futureClin Lymphoma Myeloma Leuk201515631432225445466
   PubMed Web of Science ®Google Scholar
• BinetJLAuquierADighieroGA new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisCancer1981481982067237385
   PubMed Web of Science ®Google Scholar
• RaiKRSawitskyACronkiteEPChananaADLevyRNPasternackBSClinical staging of chronic lymphocytic leukemiaBlood1975462192341139039
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNon-Hodgkin’s Lymphoma. Version 2. 2015. NCCN Clinical Practice Guidelines in Oncology Available from: http://www.nccn.orgAccessed March 1, 2015
   Google Scholar
• JaglowskiSMAlinariLLapalombellaRMuthusamyNByrdJCThe clinical application of monoclonal antibodies in chronic lymphocytic leukemiaBlood2010116193705371420610811
   PubMed Web of Science ®Google Scholar
• HallekMChronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatmentAm J Hematol201388804816
   Web of Science ®Google Scholar
• ChesonBDMonoclonal antibody therapy of chronic lymphocytic leukemiaBest Pract Res Clin Hematol201023133143
   PubMed Web of Science ®Google Scholar
• HallekMFingerle-RowsonGFinkA-MFirst-line treatment with fludarabine, cyclophosphamide, and rituximab improves overall survival in previously untreated patients with advanced chronic lymphocytic leukemia: results of a randomized phase III trial on behalf of an International Group of Investigators and the German CLL Study GroupBlood200911422535 ASH Annual Meeting Abstracts19451549
   PubMed Web of Science ®Google Scholar
• EichhorstBDreylingMRobakTMonteserratEHallekMChronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow upAnn Oncol201122suppl 6vi50vi5421908504
   PubMed Web of Science ®Google Scholar
• FischerKJBahloAMFinkRExtended follow up of the CLL8 protocol, a randomized phase III trial of the German CLL Study Group comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with CLL: results on survival, progression free survival, delayed neutropenia and secondary malignancies confirm superiority of FCR regimenBlood2012120435 ASH Annual Meeting Abstracts
   Web of Science ®Google Scholar
• HillmenPGribbenJGFollowsGARituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II studyJ Clin Oncol201432121236124124638012
   PubMed Web of Science ®Google Scholar
• Roche Pharmaceutical IncProduct Information. Rituximab (Rituxan)South San Francisco, CARoche Pharmaceutical Inc1997
   Google Scholar
• CartronGTrappeRUSolal-CelignyPHallekMInterindividual variability of response to rituximab: from biological origins to individualized therapiesClin Cancer Res2011171193021208903
   PubMed Web of Science ®Google Scholar
• Glaxo Group LimitedProduct Information. Ofatumumab (Arzerra)Brentford, UKGlaxo Group Limited2009
   Google Scholar
• Genentech IncProduct Information Obinutuzumab (Gazyva)South San FranciscoGenentech Inc2013
   Google Scholar
• SmolejLTargeted treatment of chronic lymphocytic leukemia: clinical potential of obinutuzumabPharmgenomics Pers Med201481725691812
   PubMedGoogle Scholar
• CerquozziSOwenCClinical role of obinutuzumab in the treatment of naïve patients with chronic lymphocytic leukemiaBiologics20159132225733804
   PubMedGoogle Scholar
• HoySObinutuzumab: a review of its use in patients with chronic lymphocytic leukemiaDrugs20157528529625586272
   PubMed Web of Science ®Google Scholar
• KleinCLammensASchäferWEpitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional propertiesMABs201351223123211638
   PubMed Web of Science ®Google Scholar
• GolayJDa RoitFBolognaLGlycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximabBlood20131222024822491
   Web of Science ®Google Scholar
• RafiqSButcharJPCheneyCComparative assessment of clinically utilized CD-20 directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage propertiesJ Immunol20131902702271123418626
   PubMed Web of Science ®Google Scholar
• CartronGde GuibertSDilhuydyMSObinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase I/II GAUGUIN studyBlood2014124142196220225143487
   PubMed Web of Science ®Google Scholar
• SehnLHAssoulineSESteartDA phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignanciesBlood2012119225118512522438256
   PubMed Web of Science ®Google Scholar
• BrownJRO’BrienSKingsleyCDSafety and efficacy of obinutuzumab with fludarabine/cyclophosphadmide or bendamustine in the initial therapy of patients with chronic lymphocytic leukemia: results from phase 1b Galton trial (GA04779g) abstract 52355th American Society of Hematology Annual Meeting and ExpositionSan Francisco2013
   Google Scholar
• BrownJRO’BrienSKingsleyCDObinutuzumab (G) plus fludarabine/cyclophosphamide (F-GC) or bendamustine (G-B) in the initial therapy of CLL patients: the phase 1b GALTON trialBlood20151251822792785
   Web of Science ®Google Scholar
• CartronGde GuibertSDilhuydyMSPhase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemiaBlood200911422884 ASH Annual Meeting Abstracts
   Web of Science ®Google Scholar
• CartronGMorschhauserFThieblemontCResults from a phase II study of obinutuzumab monotherapy in relapsed/refractory CLL [abstract]Haematologica201196suppl 239 Abstract 0101
   Google Scholar
• MorschhauserFSallesGCartronGDose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101) – a rational approachHaematologica201196suppl 2390
   Google Scholar
• FlynnJMByrdJCKippsTJObinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): results of the phase II GAGE (GA04768g) trialJ Clin Oncol201432suppl 5 abstract 7083
   Google Scholar
• GoedeVFischerKBuschRObinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsN Engl J Med20143701101111024401022
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKEngelkeAObinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of CLL11 studyLeukemia20152971602160425634683
   PubMed Web of Science ®Google Scholar
• GoedeVEngelkeAFischerKSalvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia and comorbidities: results of CLL11 study abstract 332756th American Society of Hematology Annual Meeting and ExpositionSan Francisco2014
   Google Scholar
• FreemanCLMorschhauserFSehnLHPattern of cytokine release in patients with chronic lymphocytic leukemia treated with obinutuzumab and possible relationship with development of infusion related reactions (IRR)Blood2014124214674
   Web of Science ®Google Scholar
• SachdevaMDhingraSObinutuzumab: a FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemiaInt J Appl Basic Med Res201551545725664270
   PubMedGoogle Scholar
• PerrilloRMartinPLokAPreventing hepatitis B reactivation due to immunosuppressive drug treatmentsJAMA2015313161617161825790287
   PubMed Web of Science ®Google Scholar
• Redbook [online database] Available from: http://www.redbook.com/redbook/onlineAccessed June 20, 2014
   Google Scholar
• Kharfan-DabajaMAWierdaWGCooperLJNImmunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitorsLeukemia20142550751724157582
   PubMedGoogle Scholar
• HillmenPSkotnickiABRobakTAlemtuzuamb compared with chlorambucil as first-line therapy for chronic lymphocytic leukemiaJ Clinc Oncol2007253556165623
   PubMed Web of Science ®Google Scholar
• StilgenbauerSDohnerHCampath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapyN Engl J Med200234745245312167696
   PubMed Web of Science ®Google Scholar
• LozanskiGHeeremaNAFlinnIWAlemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood20041033278328114726385
   PubMed Web of Science ®Google Scholar
• HillmenPRobakTJanssensAChlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukemia (COMPLEMENT 1): a randomized, multicentre, open-label phase 3 trialLancet20153851873188325882396
   PubMed Web of Science ®Google Scholar
• LadyzynskiPMolikMFoltynskiPA network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemiaCancer Treat Rev2015412779325512118
   PubMed Web of Science ®Google Scholar
• ReyesCGazauskasGBeckerUCost-effectiveness analysis of obinutuzumab versus ofatumumab for previously untreated chronic lymphocytic leukemia (CLL) [abstract 1324]56th American Society of Hematology Annual Meeting and ExpositionSan Francisco2014
   Google Scholar
• MottaGCeaMMoranEMonoclonal antibodies for non-Hodgkin’s lymphoma: state of the art and perspectivesClin Dev Immunol2010 Article ID 42825310.1155/2010/428253
   PubMedGoogle Scholar
• ShahAObinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemiaAnn Pharmacother201448101356136125037849
   PubMed Web of Science ®Google Scholar